NO20043401L - Bise-specific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods for using such - Google Patents

Bise-specific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods for using such

Info

Publication number
NO20043401L
NO20043401L NO20043401A NO20043401A NO20043401L NO 20043401 L NO20043401 L NO 20043401L NO 20043401 A NO20043401 A NO 20043401A NO 20043401 A NO20043401 A NO 20043401A NO 20043401 L NO20043401 L NO 20043401L
Authority
NO
Norway
Prior art keywords
igfbp
antisense oligonucleotides
bise
methods
inhibit
Prior art date
Application number
NO20043401A
Other languages
Norwegian (no)
Other versions
NO333017B1 (en
Inventor
Martin Gleave
Maxim Signaevsky
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of NO20043401L publication Critical patent/NO20043401L/en
Publication of NO333017B1 publication Critical patent/NO333017B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Abstract

Bispesifikke antisense-oligonukleotider som hovedsakelig består av en sekvens av baser som er komplementær med deler av både genet som koder for humant IGFBP-2 og genet som koder for humant IGFBP-5 og som er nyttige som antisense-terapeutiske midler ved behandling av endokrin-regulerte cancereBispecific antisense oligonucleotides which consist mainly of a sequence of bases which are complementary to both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 and which are useful as antisense therapeutic agents in the treatment of endocrine regulated cancers

NO20043401A 2002-01-17 2004-08-16 Bise-specific antisense oligonucleotides that inhibit IGFBP-2 and IFGBP-5 and their use, as well as pharmaceutical composition and methods for preparing it. NO333017B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
PCT/CA2003/000061 WO2003062421A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Publications (2)

Publication Number Publication Date
NO20043401L true NO20043401L (en) 2004-10-13
NO333017B1 NO333017B1 (en) 2013-02-18

Family

ID=27613360

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043401A NO333017B1 (en) 2002-01-17 2004-08-16 Bise-specific antisense oligonucleotides that inhibit IGFBP-2 and IFGBP-5 and their use, as well as pharmaceutical composition and methods for preparing it.

Country Status (15)

Country Link
US (11) US20030158143A1 (en)
EP (1) EP1465995B1 (en)
JP (1) JP4491240B2 (en)
KR (2) KR101166214B1 (en)
AT (1) ATE402999T1 (en)
AU (1) AU2003237616B2 (en)
CA (1) CA2469685C (en)
DE (1) DE60322509D1 (en)
DK (1) DK1465995T3 (en)
ES (1) ES2307942T3 (en)
HU (1) HU229452B1 (en)
IL (2) IL162540A0 (en)
NO (1) NO333017B1 (en)
NZ (1) NZ533126A (en)
WO (1) WO2003062421A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
CA2850318A1 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
KR101166214B1 (en) * 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2004018676A2 (en) * 2002-08-21 2004-03-04 The University Of British Columbia Rnai probes targeting cancer-related proteins
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
EP1560933A4 (en) * 2002-11-14 2007-11-21 Wyeth Corp Methods and compositions for treating neurological disorders
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
EP1814595B1 (en) * 2004-11-23 2014-01-08 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
EP2709673A4 (en) * 2011-05-19 2014-12-17 Teva Pharma Method for treating non-small cell lung cancer
EP2755674A4 (en) 2011-09-12 2015-04-08 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
AU2013224591A1 (en) 2012-02-22 2014-07-24 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA2844640A1 (en) * 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
SG10202104058XA (en) 2015-10-14 2021-05-28 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
AU2016341429B2 (en) 2015-10-22 2023-09-21 Cavion, Inc. Methods for treating Angelman Syndrome and related disorders
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
WO2018053232A1 (en) 2016-09-16 2018-03-22 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
CN110545806A (en) 2017-02-15 2019-12-06 卡维昂公司 calcium channel inhibitors
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
KR102068302B1 (en) 2018-07-25 2020-01-20 정준모 Envelope retainer
AU2019355021A1 (en) 2018-10-03 2021-05-06 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132813T2 (en) 1990-08-28 2002-06-27 Chiron Corp GENETIC IGFBP-5 RODING MATERIAL
WO1992003471A1 (en) 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein igfbp-5
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995017507A1 (en) 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
AU725262B2 (en) 1996-02-14 2000-10-12 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5910583A (en) 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
BR9915487A (en) 1998-11-19 2001-07-31 Warner Lambert Co N- [4- (3-chloro-4-fluoro-phenylamino) - 7 - (3-morpholin-4-yl-propoxy) -quinazolin-6-yl] -acrylamide, an irreversible inhibitor of tyrosine kinases
AU3116800A (en) 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
CA2850318A1 (en) 1999-02-26 2000-08-31 The University Of British Columbia Trpm-2 antisense therapy
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
CA2376284A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
DE60028970T2 (en) 1999-07-02 2007-02-15 Genentech Inc., San Francisco AT HER2 BINDING PEPTIDE COMPOUNDS
CA2375467C (en) * 1999-07-19 2013-10-29 The University Of British Columbia Antisense therapy for hormone-regulated tumors
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
WO2001046455A2 (en) 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2404890C (en) 2000-03-30 2013-11-19 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
WO2002022642A1 (en) * 2000-09-14 2002-03-21 The University Of British Columbia Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
BRPI0115814B8 (en) * 2000-12-01 2021-05-25 Europaeisches Laboratorium Fuer Molekularbiologie Embl double-stranded RNA molecules, their method of preparation and pharmaceutical composition comprising them
WO2002097114A2 (en) 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US6750019B2 (en) * 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (en) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolyl substituted heterocycles
AU2002353891A1 (en) 2001-10-25 2003-05-06 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
KR101166214B1 (en) 2002-01-17 2012-07-16 더 유니버시티 오브 브리티쉬 콜롬비아 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
CA2485589A1 (en) 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
EP1530636B1 (en) 2002-08-21 2010-08-18 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004018676A2 (en) 2002-08-21 2004-03-04 The University Of British Columbia Rnai probes targeting cancer-related proteins
WO2004092378A2 (en) 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
BR112012002102A2 (en) * 2009-07-30 2017-05-02 Antisense Pharma Gmbh pharmaceutical composition and method for preparing a pharmaceutical composition

Also Published As

Publication number Publication date
HUP0402543A3 (en) 2012-09-28
ATE402999T1 (en) 2008-08-15
JP4491240B2 (en) 2010-06-30
US8580761B2 (en) 2013-11-12
US20060122141A1 (en) 2006-06-08
IL162540A (en) 2011-06-30
US20120220646A1 (en) 2012-08-30
KR101166214B1 (en) 2012-07-16
KR20040085150A (en) 2004-10-07
US20030158143A1 (en) 2003-08-21
US8470796B2 (en) 2013-06-25
IL162540A0 (en) 2005-11-20
NO333017B1 (en) 2013-02-18
US8389491B2 (en) 2013-03-05
EP1465995B1 (en) 2008-07-30
AU2003237616B2 (en) 2007-07-05
US8835401B2 (en) 2014-09-16
US7928082B2 (en) 2011-04-19
HUP0402543A2 (en) 2005-03-29
US20110190382A1 (en) 2011-08-04
KR20110026023A (en) 2011-03-14
EP1465995A1 (en) 2004-10-13
US7973017B2 (en) 2011-07-05
KR101265180B1 (en) 2013-05-29
DK1465995T3 (en) 2008-10-20
US8252765B2 (en) 2012-08-28
WO2003062421A1 (en) 2003-07-31
JP2005514948A (en) 2005-05-26
US20160002630A1 (en) 2016-01-07
US20130096180A1 (en) 2013-04-18
US9101646B2 (en) 2015-08-11
CA2469685C (en) 2013-03-12
US20120077861A1 (en) 2012-03-29
CA2469685A1 (en) 2003-07-31
US20110196019A1 (en) 2011-08-11
DE60322509D1 (en) 2008-09-11
NZ533126A (en) 2006-04-28
US20100267808A1 (en) 2010-10-21
US20080261912A1 (en) 2008-10-23
HU229452B1 (en) 2013-12-30
ES2307942T3 (en) 2008-12-01
US8541390B2 (en) 2013-09-24
US20130303592A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
NO20043401L (en) Bise-specific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods for using such
EP1628623A4 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
IL175427A0 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
DK1809280T3 (en) Mitotic kinesin inhibitors and methods for their use
MY151032A (en) Treatment of tnf? related disorders
AU2003213771A8 (en) Method for modification of radiotherapy treatment delivery
EP1755643A4 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
SI1862458T1 (en) Therapeutic agents useful for treating pain
ATE418336T1 (en) USE OF I KAPPA B-KINASE INHIBITORS IN PAIN THERAPY
IL164808A0 (en) Treatment of hypertesion in women receiving hormone replacement therapy
AU2003287254A8 (en) Inhibition of gene expression using rna interfering agents
AU2003243059A8 (en) Use of repression blocking sequences in methods for enhancing gene expression
TW200508233A (en) Chk-1 inhibitors
EP1579010A4 (en) Susceptibility gene for myocardial infarction; methods of treatment
EP1827458A4 (en) Selective inhibition of rock 1 in cardiac therapy
IL176239A0 (en) Use of gaboxadol for treating insomnia
TW200628168A (en) Use of organic compounds
MXPA05011699A (en) Agents for the treatment of lower abdominal disorders.
EP1601325A4 (en) Antisense oligonucleotides that inhibit expression of hif-1
PL377040A1 (en) Method of treatment of myocardial infarction
MXPA05008817A (en) Nucleotide lipid ester derivatives.
PT1163333E (en) Inhibitors of endothelin-1 synthesis
IL154293A0 (en) Process of treating dates
AR034022A1 (en) ACRIDINES AS STIMULATORS OF PHAS-APPROVED APOPTOSIS
AU2003286931A8 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees